New Leaf Venture Partners announced today that General Partner Liam Ratcliffe, M.D., Ph.D., has been elected as Independent Director to the Board of Directors of Array BioPharma Inc. Dr. Ratcliffe has extensive background in drug development and translational medicine, including a 12-year tenure at Pfizer.
“We are excited to announce Liam’s addition to the Array Board of Directors,” said Kyle Lefkoff, Chairman of Array BioPharma. “We believe Liam’s background in drug development will be immensely helpful as Array further advances its broadening product portfolio in oncology, as well as other major disease indications.”
Dr. Ratcliffe commented, “This is an important time for Array. As announced separately, new CEO Ron Squarer joins the Company, providing his unique outlook and perspective, and Array expects multiple data readouts from its clinical programs through the rest of 2012.”
Dr. Ratcliffe continued, “I’m honored to join the Array Board as an independent director, and I look forward to fulfilling a role in which I can reflect the broad interests of Array’s diverse shareholder base.”
Prior to joining NLV Partners, Dr. Ratcliffe served as senior vice president and development head for Pfizer Neuroscience, as well as worldwide head of Clinical Research and Development. Additional positions at Pfizer included vice president of Exploratory Development for the Mid West region, and head of Experimental Medicine at Pfizer's Sandwich, UK Laboratories.
Dr. Ratcliffe received his M.D. and Ph.D. degrees in immunology from the University of Cape Town and his MBA degree from the University of Michigan. He completed his internal medicine training and fellowship in Immunology at Groote Schuur Hospital and additional teaching hospitals in Cape Town, South Africa.
Join the Conversation